Jubilant Biosys Enters Into Drug Discovery Collaboration With Orion

Jubilant Biosys has announced that it is entering into a drug discovery collaboration with Orion Corporation. Jubilant is based out of Bengaluru while Orion is the largest pharmaceutical company in Finland. The companies will be working together to discover small molecule inhibitors in the neuroscience therapeutic area in order to develop a drug for pain management in patients with unmet needs in the pain management area.

Jubilant will be providing drug discovery services, including scale-up and pre-clinical services. The research will take place at Jubilant facilities in both India and the U.S.

Orion will provide research funding and royalties to Jubilant while retaining ownership of any compounds developed.  The company will also be keeping exclusive worldwide rights for the use of those compounds. According to the press release, research has already started at the Jubilant facilities. The release does not specify a time table for the completion of the companies’ research.

Subir Kumar Basak, President of Jubilant, says, “We are excited to partner with Orion to offer integrated drug discovery services. Over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts. We are confident of offering successful results to Orion at various stages of research.”

Head of CNS Research of Orion Pharma Research & Development, Jukka Sallinen, says that this collaboration will benefit Orion. “Jubilant Biosys is widely recognized for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation,” he said. According to Sallinen, this strategic partnership will help the company bring its product efficiently into the market, as Jubilant has established its identity as a developer of high quality drugs.